Pharmaceutical Statistics

Aims & Scope

Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications.

The Journal publishes papers that share experiences in the practical application of statistics within the pharmaceutical industry.

It covers all aspects of pharmaceutical statistical applications from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics.

The Journal is both international and multidisciplinary.

It includes high quality practical papers, case studies and review papers.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	1.4
2024	1.30

SJR (SCImago Journal Rank)

Year	Value
2024	1.074

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	49

Journal Rank

Year	Value
2024	4283

Journal Citation Indicator

Year	Value
2024	503

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Mathematics, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies

  Citation: 2993

  Authors: Peter C.

• Sample size of 12 per group rule of thumb for a pilot study

  Citation: 2209

  Authors: Steven A.

• Guidelines for accurate EC50/IC50 estimation

  Citation: 716

  Authors: J. L.

• Use of historical control data for assessing treatment effects in clinical trials

  Citation: 416

  Authors: Kert, Scott, Beat, Billy, Fang, Nathan, Brian, Joseph G., Nelson, Stacy, Sandrine, Satrajit, Laura

• Consequences of dichotomization

  Citation: 236

  Authors: Valerii, Frank, Rongmei

• Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

  Citation: 227

  Authors: Sue‐Jane, Robert T., H. M. James

• Assurance in clinical trial design

  Citation: 224

  Authors: Anthony, John W., Michael J.

• Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches

  Citation: 204

  Authors: Peter

• Using confidence intervals around individual means to assess statistical significance between two means

  Citation: 186

  Authors: Steven A.

• An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†

  Citation: 174

  Authors: Martin, Andrew, Christopher

---